Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become a mainstay of cancer treatment. Their immune-boosting quality has one major drawback, their proclivity to induce a broad array of immune-related adverse events (irAEs) affecting, among others, the liver and sharing some similarities with cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Coukos, Alexander, Vionnet, Julien, Obeid, Michel, Bouchaab, Hasna, Peters, Solange, Latifyan, Sofiya, Wicky, Alexandre, Michielin, Olivier, Chtioui, Haithem, Moradpour, Darius, Fasquelle, François, Sempoux, Christine, Fraga, Montserrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608549/
https://www.ncbi.nlm.nih.gov/pubmed/36283734
http://dx.doi.org/10.1136/jitc-2022-005635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608549/
https://www.ncbi.nlm.nih.gov/pubmed/36283734
http://dx.doi.org/10.1136/jitc-2022-005635

Ejemplares similares